当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Jenny Williams
Biotechnology businesses face moral challenges of two wonderful types: bioethical challenges confronted on account of the nature of work in the existence sciences, and corporate moral challenges on account of their nature as business entities. The latter set of challenges has obtained nearly no interest at all in the educational literature or media. This paper starts off evolved to treatment that lacuna, inspecting moral troubles that occur specially on account of the repute of biotech businesses as industrial entities. The center of attention right here is on three consultant issues: product safety, company social responsibility, and company governance. It is argued that every of these troubles pose specific moral challenges for businesses in the biotech sector. In the place of product safety, it is cited that biotech groups face unique challenges in figuring out what counts as a "safe" product, given the contentious nature of what would possibly count number as a "harm" in the biotech field.